Iterum Therapeutics plc (NasdaqCM:ITRM) provided a general business update. Iterum plans to engage a financial advisor in the near-term to assist management and the Board in evaluating Iterum?s strategic alternatives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.52 USD | -1.94% | -4.40% | -22.84% |
May. 10 | Iterum Therapeutics plc Announces Executive Changes | CI |
Apr. 29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.84% | 25.66M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives